First Drug Treatment for Peanut Allergy Receives FDA Approval
February 3rd 2020Officials with the FDA have approved Aimmune Therapeutics’ Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
FDA Expands Topical Treatment Options for Adolescents with Plaque Psoriasis
July 31st 2019Officials with the FDA have taken action on LEO Pharma’s calcipotriene and betamethasone dipropionate foam and topical suspension products for the topical treatment of plaque psoriasis in patients age 12 years and older.
Possible Link Between Seizure and E-Cigarette Use Under FDA Investigation
April 3rd 2019According to the FDA, seizures are known potential adverse effects of nicotine poisoning and have been reported in scientific literature in relation to intentional or accidental swallowing of nicotine-containing e-liquids.
First Drug Therapy for PostPartum Depression Receives FDA Approval
March 20th 2019Tiffany Farchione, MD, acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said in a prepared statement that the approval provides an important new treatment option for PPD.
Providing Care for Children With Headache
March 19th 2019In a session presented at the National Association of Pediatric Nurse Practitioners national conference in New Orleans, Elizabeth Rende, DNP, CPNPâ€PC, PMHSâ€BC, FAAN with Duke Pediatric Neurology said up to 85% of pediatric patients have had a significant headache event by age 15 years.
Menstruation: A Vital Tool for Assessing Health in Females
March 9th 2019At the 40th National Conference of the National Association of Pediatric Nurse Practitioners, in New Orleans, experts presenting a session on menstrual management said that amenorrhea and heavy menstrual bleeding (HMB) can both indicate a variety of medical issues in the pediatric patient population.
IV Bags Shortages are Affecting Antibiotic Delivery Methods
December 20th 2018A shortage of intravenous bags has impacted the way that many hospitals and health systems have delivered many parenteral products in recent months, with many health systems opting for intravenous (IV) push delivery methods as an alternative to other options.